AstraZeneca beat second-quarter profit expectations and reaffirmed its 2026 guidance on strong demand for its cancer and heart disease therapies, even as concerns linger about longer-term growth after a recent trial setback. Analysts are Eyeing Q2 2026 earnings around $2.10 per share on approximately $15.44 billion in revenue, following a prior quarter that beat expectations with $2.58 per share on $15.29 billion in revenue. Market sentiment on AZN is mixed-to-bullish, with an average Moderate Buy rating across covering brokerages and several banks reiterating Buy calls or nudging targets higher. Investors are closely watching the upcoming earnings and the company’s oncology pipeline, which accounts for a large portion of revenue, as global markets react to broader market moves. AZN trades around a price-earnings ratio near 25.45, close to its five-year median, while insiders have sold about $2.2 million worth of shares in the last three months. AstraZeneca operates across oncology, cardiovascular, renal and metabolism, with a presence in over 100 countries and a pipeline that underpins its growth outlook.